BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 33863500)

  • 1. Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma.
    Lahman MC; Paulson KG; Nghiem PT; Chapuis AG
    J Invest Dermatol; 2021 Aug; 141(8):1897-1905. PubMed ID: 33863500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.
    Miller NJ; Church CD; Fling SP; Kulikauskas R; Ramchurren N; Shinohara MM; Kluger HM; Bhatia S; Lundgren L; Cheever MA; Topalian SL; Nghiem P
    J Immunother Cancer; 2018 Nov; 6(1):131. PubMed ID: 30482247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Merkel cell polyomavirus-specific CD8⁺ and CD4⁺ T-cell responses identified in Merkel cell carcinomas and blood.
    Iyer JG; Afanasiev OK; McClurkan C; Paulson K; Nagase K; Jing L; Marshak JO; Dong L; Carter J; Lai I; Farrar E; Byrd D; Galloway D; Yee C; Koelle DM; Nghiem P
    Clin Cancer Res; 2011 Nov; 17(21):6671-80. PubMed ID: 21908576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
    Vandeven N; Nghiem P
    Immunotherapy; 2016 Jul; 8(8):907-21. PubMed ID: 27381685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.
    Colunga A; Pulliam T; Nghiem P
    Clin Cancer Res; 2018 May; 24(9):2035-2043. PubMed ID: 29217527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications.
    Walsh NM; Castonguay MC; Carter MD; Pasternak S; Ly TY; Doucette S; Hanly JG; Saggini A; Cerroni L
    Am J Dermatopathol; 2019 Nov; 41(11):819-825. PubMed ID: 31634167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development.
    Tabachnick-Cherny S; Pulliam T; Church C; Koelle DM; Nghiem P
    Mol Carcinog; 2020 Jul; 59(7):807-821. PubMed ID: 32219902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer.
    Akaike T; Nghiem P
    J Dermatol Sci; 2022 Jan; 105(1):2-10. PubMed ID: 34836718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
    Paulson KG; Bhatia S
    J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the IDO1/TDO2-AhR pathway in tumor cells or the tumor microenvironment is associated with Merkel cell polyomavirus status and prognosis in Merkel cell carcinoma.
    Wardhani LO; Matsushita M; Iwasaki T; Kuwamoto S; Nonaka D; Nagata K; Kato M; Kitamura Y; Hayashi K
    Hum Pathol; 2019 Feb; 84():52-61. PubMed ID: 30240768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.
    Paulson KG; Voillet V; McAfee MS; Hunter DS; Wagener FD; Perdicchio M; Valente WJ; Koelle SJ; Church CD; Vandeven N; Thomas H; Colunga AG; Iyer JG; Yee C; Kulikauskas R; Koelle DM; Pierce RH; Bielas JH; Greenberg PD; Bhatia S; Gottardo R; Nghiem P; Chapuis AG
    Nat Commun; 2018 Sep; 9(1):3868. PubMed ID: 30250229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.
    Lipson EJ; Vincent JG; Loyo M; Kagohara LT; Luber BS; Wang H; Xu H; Nayar SK; Wang TS; Sidransky D; Anders RA; Topalian SL; Taube JM
    Cancer Immunol Res; 2013 Jul; 1(1):54-63. PubMed ID: 24416729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of significant morphologic characteristics in distinguishing between Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative Merkel cell carcinomas.
    Iwasaki T; Matsushita M; Kuwamoto S; Kato M; Murakami I; Higaki-Mori H; Nakajima H; Sano S; Hayashi K
    Hum Pathol; 2013 Sep; 44(9):1912-7. PubMed ID: 23664542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust Production of Merkel Cell Polyomavirus Oncogene Specific T Cells From Healthy Donors for Adoptive Transfer.
    Davies SI; Barrett J; Wong S; Chang MJ; Muranski PJ; Brownell I
    Front Immunol; 2020; 11():592721. PubMed ID: 33362774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Merkel cell polyomavirus and its involvement in Merkel cell carcinoma.
    Amber K; McLeod MP; Nouri K
    Dermatol Surg; 2013 Feb; 39(2):232-8. PubMed ID: 23387356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
    Goh G; Walradt T; Markarov V; Blom A; Riaz N; Doumani R; Stafstrom K; Moshiri A; Yelistratova L; Levinsohn J; Chan TA; Nghiem P; Lifton RP; Choi J
    Oncotarget; 2016 Jan; 7(3):3403-15. PubMed ID: 26655088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients.
    Ricci C; Righi A; Ambrosi F; Gibertoni D; Maletta F; Uccella S; Sessa F; Asioli S; Pellilli M; Maragliano R; La Rosa S; Papotti MG; Asioli S
    Endocr Pathol; 2020 Mar; 31(1):21-32. PubMed ID: 31808008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts and approaches to merkel cell carcinoma.
    Babadzhanov M; Doudican N; Wilken R; Stevenson M; Pavlick A; Carucci J
    Arch Dermatol Res; 2021 Apr; 313(3):129-138. PubMed ID: 32666149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of Protein Kinase C ε in Merkel Cell Polyomavirus-Induced Merkel Cell Carcinoma.
    Costa A; Mackelfresh J; Gilbert L; Bonner MY; Arbiser JL
    JAMA Dermatol; 2017 Sep; 153(9):931-932. PubMed ID: 28564697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Working Group for Dermatologic Oncology (ADO)].
    Becker JC
    J Dtsch Dermatol Ges; 2008 Jun; 6(6):525. PubMed ID: 18494721
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.